Nodthera
5 known investors
NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation. The company operates in the biotechnology and drug development sector.
Founders & leadership
GM
Geoff McDonoughExecutive Team / Board
CG
Chris GuiffreExecutive Team
AP
Alan P. WattExecutive Team
JG
Jyothis GeorgeChief Medical Officer
NC
Nick ClarkeExecutive Team
Investors · 5
Competitors · 7
by search overlapRayThera14 shared keywordsRayThera develops small molecule therapies targeting unmet needs in immunology. The company focuses on drug discovery in the biotechnology and immunology space.
SonoThera14 shared keywordsSonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way. The company works on genetic medicine, aiming to address limitations in delivery, safety, durability, and cost.
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Neurona Therapeutics13 shared keywordsNeurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter>
<parameter name="founders">[]
AltaThera Pharmaceuticals11 shared keywordsAltaThera Pharmaceuticals develops hospital-use intravenous drug therapies for treating cardiovascular conditions such as atrial fibrillation, atrial flutter, and ventricular arrhythmias in adult and pediatric patients. Its intravenous approach to antiarrhythmic initiation aims to enable faster therapeutic assessment and more precise dosing for physicians in hospital settings.
Actithera10 shared keywordsActithera develops radioligand therapies (RLT) for cancer, using proprietary molecular design and chemistry to create compounds that concentrate in tumors while sparing healthy tissue. The company designs molecules that match radionuclide half-life with tumor residence time to enable effective treatment with fewer therapy cycles, with some compounds being prepared for clinical trials.
KayoThera10 shared keywordsKayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology. The company is led by an experienced management team supported by scientific and clinical advisory boards.
Companies competing with Nodthera for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Nodthera do?
- NodThera develops clinical-stage small-molecule therapies targeting inflammation for cardiometabolic and neuroinflammatory diseases, including cardiovascular disease, metabolic dysfunction, and neuroinflammation. The company operates in the biotechnology and drug development sector.
- Who are Nodthera's investors?
- Nodthera's investors include 5AM Ventures, Epidarex Capital, F-Prime Capital, Sanofi Ventures, Sofinnova Partners.